Ovagen 20mg we yu de yuz

▎ we di Ovagen gɛt Di Strukchɔ

▎ fɔ Ovagen Risach

Wetin na di risach bakgrɔn fɔ Ovagen?

Insay di we aw pipul dɛn de liv de chenj—we na di pɔyzin we de na di envayrɔmɛnt we de bɔku, we dɛn de yuz antibayɔtik pasmak, bɔku bɔku kemotɛrapi ɛn redio tɛrapi, ɛn di pipul dɛn we de ol—di sik dɛn we de na di liva ɛn bɛlɛ dɔn go ɔp bad bad wan. Kɔndishɔn lɛk kronik pɔsitiv ɛpatitis ɛn sirosis kin rili ambɔg di sik pipul dɛn kwaliti fɔ layf ɛn wɛlbɔdi. Tradishɔnal tritmɛnt dɛn kin strɛs fɔ mek di liva ɛn bɛlɛ intestinal wok fayn fayn wan, dɛn nɔ kin ebul fɔ protɛkt ɛn trit sik dɛn we difrɛn tin dɛn we kin mek pɔsin gɛt, ɛn dɛn kin sho se dɛn nɔ ebul fɔ ɛp fɔ mek di prɔblɛm dɛn we kin kam wit redio tɛrapi, kemotɛrapi, ɛn di sayd ifɛkt dɛn we antibayɔtik kin gɛt. Dis de ɔndaskayn di urgent nid fɔ nyu tritmɛnt aprɔch dɛm.

di pεptayd dεm, bikoz fכ dεn difrεn strכkchכ dεm, kin intarakt wit mכltipכl intasεlulyar mכlikul dεm, we de infכlכ di sεl prכsεs dεm lεk mεtabolism, growth, εn ripa. di kכrכm kכmכpכnt dεm na di ovajen inklud pεptida kכmpleks dεm we kכmכp fכ spεsifi k amino asid dεm, lεk AC-3 we glutamik asid, aspartik asid, εn lכsin fכm. dis kכmכshכn de infכlכ in rεgεdyushכn mεkanism dεm pan di liva εn gεstrointestinal fכnshכn. Tru risach pan Ovagen, sayɛnsman dɛn dɔn fɛn wan we we go wok mɔ fɔ chenj di liva ɛn gastrointestinal wok fɔ mit di klinik tritmɛnt ɛn di nid fɔ mek dɛn nɔ gɛt sik.

Wetin na di we aw Ovagen de du tin?

Risεptor Binding de Initiate Signal Transdukshכn

spεsifi k rεsεpכta binding: bכku pεptida כmon dεm de εksyεrt dεn ifekt bay we dεn de biεn spεsifi k hεy-affiniti rεsεpכta dεm, we na intagrεd protin dεm we de span di plasma mεmbran. εvri pεptida כmon de intarakt wit in dεsignεt rεsεpכta lεk wan ki we de fit lכk, we de mek sכh se di signal transmishכn prεsis. we dεn biεn, wan kaskad fכ bayokεmik ivent dεm de kכnekt di fכs sayt fכ di pεptida כmon akshכn—di plasma mεmbran—to difrεn tכgεt sεl rεspכns dεm ^[1,2]..

Aktibכt Sayn Pathways: rεsεptor-pεptida binding de aktibכt intasεlulyar signal path dεm. fכ egzampl, sכm pεptida כmon dεm de biεn di rεsεpכta dεm we de aktibכt adenylate cyclase, we de protεkt di prodyushכn fכ di intasεlulyar sεkכn mεsenja saykli AMP (cAMP). as ki mεsenja, cAMP de aktibכt protin kinaz dεm, we de lid to di fכsfכrayleshכn fכ spεsifi k sabstεrayt dεm εn rεgεl di tכgεt sεl fכnshכn dεm. insay sכm tכgεt tisu dεm, lεk di liva εn di adipos tisu, cAMP de wok as di praymar sεkכn mεsenja we de trigεr כmon-spεsifi k bayokεmik rεspכns dεm. biyכn cAMP, כda signal path dεm εn mεsenja mכlikul dεm de tek pat pan pεptida mεkanism dεm; fכ egzampl, di kalsiכm ayכn dεm de ple imכtant rol fכ rεgεl di sεl dεm we de ansa na sכm tisu dεm ^{[2] .}.

fig 1 dayagram fכ di path dεm we de involv fכ rεgεl di stεroydכjεnεsis insay di gonadal tisu bay luteinizing כmon ^[2]..

Wetin na di wok we Ovagen de du?

di ovajen de mek di εpatosayt gro εn i de mek di liva fibrosis εn sirosis nכ de. i de mek di liva wok fayn bay we i de rεgεl di hεpatosayt DNA strכkchכ εn di transkripshכn patεn dεm. ovagen de sho bak anti-aging ifekt dεm, we de rivεs di εj-rεlatεd DNA כltεrayshכn fכ rεstכr di εpatosayt dεm to mכr yכŋ stet. Ovagen de mek di gεstrointestinal mכkus barεri fכ wok fayn, i de mek di gεstrointestinal mכkus barεri fכ wok fayn, i de mek di gεstrointestinal trakt dεm we de kכz fכ tin dεm lεk antibaytik tεrapi, di tכxin dεm we de na di envayroment, kεmothεrapi, εn mכlnutrishכn. in rεgεdyushכn ifekt dεm pan liva εn gεstrointestinal fכnshכn akraos difrεn inflammatory εn sik stet dεm de gi brayt aplikεshכn prכspεkt. Dɛn kin yuz am fɔ kia fɔ dɛn afta dɛn dɔn ɔpreshɔn, fɔ trit antibayɔtik fɔ lɔng tɛm, fɔ mek di sayd ɛfɛkt dɛn we kin kam pan kansa tritmɛnt, ɛn fɔ mek dɛn nɔ gɛt dayabitis.

Ovagen ɛn HIV

Ovagen dכn gεt atεnshכn insay HIV risach biכs fכ in demonstret inhibitory ifekt pan HIV-1 protease. HIV-1 protease na imכtant εnzym fכ di vayral sכvayvεns, we de rispansabl fכ kכl di vayral protin dεm to fכnshכnal sכbyunit dεm. as HIV-1 protease inhibitor, Ovagen de pan di sכm sכm εn pawaful protease inhibito dεm we dεn no. Dis inhibitory akshכn kin εp fכ kכntrכl HIV rεplikεshכn, we de opin nyu avεnyu fכ HIV tritmεnt risεch.

Risach we Badaya A du sho se Ovagen kin inhibit HIV-1 protease aktiviti ^[3] . HIV-1 protease na imכtant εnzym insay di vayral rεplikshכn, we de rispansabl fכ kכl di polyprotein dεm fכ machכ εn asembl dεm to infεkshכn vayral patikyula dεm. inhibit protease aktiviti de disrupt di vayral rεplikshכn prכsεs ^[3] . ovagen de inhibit protease katalytik fכnshכn bay we i de biεn in aktv sayt כ altεr in kכnfכmeshכn. bay we i de biεn di aktv sayt, i de mek di sabstεrayt nכ go insay εn di klivεj riakshכn ^{[3] .}.

Dɔn

ovajen na tripεptida kכmpawnd we de sho mכlti fכs bayolojikal aktiviti dεm, fכs fכ rεgεl di liva εn gεstrointestinal fכnshכn dεm. i de mek di εpatosayt gro, i de mek di liva fכ fכm εn sirosis, i de mek di liva wok fayn bay we i de mכdulet di DNA strכkchכ εn di transkripshכnal patεn dεm, εn i de sho se i ebul fכ ol. Ovagen de mek di gastrointestinal mucosal barrier function strɔng, i de mek di damej we antibayɔtik, invayrɔmɛnt pɔyzin, kemotɛrapi, ɛn malnutrishɔn nɔ bɔku.

ovajen na tripεptida kכmpawnd wit mכlti fכs bayolojikal aktiviti dεm, fכs fכ rεgεl di liva εn gεstrointestinal fכnshכn. i de mek di εpatosayt gro, i de mek di liva fכ fכm εn sirosis, i de mek di liva fכ wok fayn bay we i de mכdulet di DNA strכkchכ εn di transkripshכnal patεn, εn i de sho anti-aging pכtεnshal. Ovagen de mek di gastrointestinal mucosal barrier function strɔng, i de mek di damej we antibayɔtik, envayrɔmɛnt pɔyzin, kemotɛrapi, ɛn malnutrishɔn de mek nɔ bɔku.

Bɔt di pɔsin we rayt di buk

Di tin dɛn we wi dɔn tɔk bɔt ɔp, na ɔl di tin dɛn we Cocer Peptides dɔn du risach, ɛdit ɛn kɔmpilayt.

Sayɛns Jɔnal Author

Apoorva Badaya na wan risachman we spɛshal pan kɔmpyuta bayɔfiziks ɛn strɔkchɔral bayɔinfɔmatiks. i gεt kכ-autכr stכdi dεm we de fכkus pan di mכlikul dynamiks fכ HIV-1 protez, patikyular in rilayshכn to antibodi binding εn mכtεshכn. in wok de employ advans simulεshכn tεknik fכ εksplכr protin dinamiks εn infכm tεrapi stratεji dεm. Apoorva Badaya de na di list insay di rɛfrɛns fɔ saytayshɔn [3].

▎ Saytayshɔn dɛn we gɛt fɔ du wit dis

[1] Barker S. Mεkanism fכ akshכn fכ pεptida כmon dεm; 2020: 47-71.DOI: 10.1201/9781003076926-3.

[2] K., J., Katf., ɛn ɔda pipul dɛn. BεSIK KכNSεPT DεN Fכ DI MEKANISM Fכ AKSHכN Fכ PεPTAYD HכMכN DεN.; 2004. https://api.semanticscholar.org/CorpusID:250184627. Di wan dɛn we de stɔdi bɔt di Baybul.

[3] Badaya A, Sasidhar Y. U., ɛn ɔda pipul dɛn. inhibishכn fכ di aktvכti fכ HIV-1 protez tru antibodi binding εn mכtεshכn dεm we dεn prob bay mכlikul dynamiks simulεshכn. Sayɛns Ripɔt dɛn 2020; 10 (1): 5501.DOI: 10.1038/s41598-020-62423-y.

ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL FƆ DI INFƆMƐSHƆN ƐN FƆ EDYUKESHƆN.  

Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto mɛrɛsin, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.